Wine phenolics, Ann. N. Y. Acad. Sci, vol.957, pp.21-36, 2002. ,
Of the phenolic substances of white hellbore (veratrum grandiflorum loes, Fil.). J. Fac. Sci. Hokkaido Imp. Univ, vol.3, pp.1-16, 1940. ,
Chemical constituents of polygonaceous plants. I. Studies on the components of ko-j o-kon. (polygonum cuspidatum sieb. Et zucc.), Yakugaku zasshi J. Pharm. Soc. Jpn, vol.83, pp.254-264, 1963. ,
, Cancer chemopreventive activity of resveratrol, vol.275, pp.218-220, 1997.
The pharmacology of resveratrol in animals and humans, Biochim. Biophys. Acta, vol.1852, pp.1071-1113, 2015. ,
Therapeutic potential of resveratrol: The in vivo evidence, Nat. Rev. Drug Discov, vol.5, pp.493-506, 2006. ,
Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence, Curr. Pharm. Des, vol.19, pp.6064-6093, 2013. ,
Cellular effects of resveratrol in skeletal muscle, Life Sci, vol.84, pp.637-640, 2009. ,
Muscle mitochondria and insulin resistance: A human perspective, Trends Endocrinol. Metab, vol.23, pp.444-450, 2012. ,
Resveratrol improves health and survival of mice on a high-calorie diet, Nature, vol.444, pp.337-342, 2006. ,
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha, Cell, vol.127, pp.1109-1122, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00188005
The biochemistry and physiology of mitochondrial fatty acid beta-oxidation and its genetic disorders, Ann. Rev. Physiol, 2015. ,
Carnitine palmitoyltransferases 1 and 2: Biochemical, molecular and medical aspects, Mol. Asp. Med, vol.25, pp.495-520, 2004. ,
Muscle carnitine palmitoyltransferase ii deficiency: Clinical and molecular genetic features and diagnostic aspects, Arch. Neurol, vol.62, pp.37-41, 2005. ,
Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship, Hum. Mutat, vol.18, pp.169-189, 2001. ,
Bezafibrate for treatment of an inborn mitochondrial ?-oxidation defect, N. Engl. J. Med, vol.360, pp.838-840, 2009. ,
Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency, Clin. Pharmacol. Ther, vol.88, pp.101-108, 2010. ,
A delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency, Mol. Genet. Metab, vol.96, pp.85-90, 2009. ,
Current issues regarding treatment of mitochondrial fatty acid oxidation disorders, J. Inherit. Metab. Dis, vol.33, pp.555-561, 2010. ,
Ppars as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders, J. Inherit. Metab. Dis, vol.31, pp.217-225, 2008. ,
Drug repositioning for orphan diseases, Brief. Bioinform, vol.12, pp.346-356, 2011. ,
Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts, Hum. Mol. Genet, 2011. ,
Stilbenes and resveratrol metabolites improve mitochondrial fatty acid oxidation defects in human fibroblasts, Orphanet J. Rare Dis, vol.9, p.79, 2014. ,
Metabolic effects of resveratrol: Addressing the controversies, Cell. Mol. Life Sci, vol.72, pp.1473-1488, 2015. ,
The molecular targets of resveratrol, Biochim. Biophys. Acta, vol.1852, pp.1114-1123, 2015. ,
Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis, Am. J. Clin. Nutr, vol.93, pp.884-890, 2011. ,
Small molecule activators of sirtuins extend saccharomyces cerevisiae lifespan, Nature, vol.425, pp.191-196, 2003. ,
Mechanism of human sirt1 activation by resveratrol, J. Biol. Chem, vol.280, pp.17187-17195, 2005. ,
Substrate-specific activation of sirtuins by resveratrol, J. Biol. Chem, vol.280, pp.17038-17045, 2005. ,
and resveratrol are not direct activators of SIRT1, J. Biol. Chem, vol.285, pp.8340-8351, 2010. ,
Resveratrol stimulates amp kinase activity in neurons, Proc. Natl. Acad. Sci, vol.104, pp.7217-7222, 2007. ,
Sirt1 regulates hepatocyte lipid metabolism through activating amp-activated protein kinase, J. Biol. Chem, vol.283, 2008. ,
Sirt1 is required for ampk activation and the beneficial effects of resveratrol on mitochondrial function, Cell Metab, vol.15, pp.675-690, 2012. ,
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting camp phosphodiesterases, Cell, vol.148, pp.421-433, 2012. ,
Monogenic mitochondrial disorders, N. Engl. J. Med, vol.366, pp.1132-1141, 2012. ,
Mitochondrial complex i deficiency: From organelle dysfunction to clinical disease, Brain J. Neurol, vol.132, pp.833-842, 2009. ,
Emerging concepts in the therapy of mitochondrial disease, Biochim. Biophys. Acta, vol.1847, pp.544-557, 2015. ,
PGC-1 coactivators: Inducible regulators of energy metabolism in health and disease, J. Clin. Investig, vol.116, pp.615-622, 2006. ,
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism, Endocr. Rev, vol.27, pp.728-735, 2006. ,
Beneficial effects of resveratrol on respiratory chain defects in patients' fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling, Hum. Mol. Genet, vol.23, pp.2106-2119, 2014. ,
Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta, Endocrinology, vol.141, pp.3657-3667, 2000. ,
Estrogen related receptors (errs): A new dawn in transcriptional control of mitochondrial gene networks, vol.11, pp.544-552, 2011. ,
Screening for active small molecules in mitochondrial complex i deficient patient's fibroblasts, reveals aicar as the most beneficial compound, PLoS ONE, vol.6, 2011. ,
Effect of resveratrol on cultured skin fibroblasts from patients with oxidative phosphorylation defects, Phytother. Res. PTR, vol.28, pp.312-316, 2014. ,
Influence of exercise training with resveratrol supplementation on skeletal muscle mitochondrial capacity, Appl. Physiol. Nutr. Metab, vol.41, pp.26-32, 2016. ,
Experimental studies of the molecular pathways regulated by exercise and resveratrol in heart, skeletal muscle and the vasculature, Molecules, vol.19, pp.14919-14947, 2014. ,
Can resveratrol help to maintain metabolic health?, Proc. Nutr. Soc, vol.73, pp.271-277, 2014. ,
Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment, EMBO Rep, vol.5, pp.872-876, 2004. ,
The cell biology of disease: Cellular and molecular mechanisms underlying muscular dystrophy, J. Cell Biol, vol.201, pp.499-510, 2013. ,
Pathophysiology of duchenne muscular dystrophy: Current hypotheses. Pediatri. Neurol, vol.36, pp.1-7, 2007. ,
Revisiting the dystrophin-atp connection: How half a century of research still implicates mitochondrial dysfunction in duchenne muscular dystrophy aetiology, vol.85, pp.1021-1033, 2015. ,
The mdx mouse model as a surrogate for duchenne muscular dystrophy, FEBS J, vol.280, pp.4177-4186, 2013. ,
Fast muscle fibers are preferentially affected in duchenne muscular dystrophy, Cell, vol.52, pp.503-513, 1988. ,
The therapeutic potential of skeletal muscle plasticity in duchenne muscular dystrophy: Phenotypic modifiers as pharmacologic targets, FASEB J, vol.28, pp.548-568, 2014. ,
PGC-1alpha regulates the neuromuscular junction program and ameliorates duchenne muscular dystrophy, Genes Dev, vol.21, pp.770-783, 2007. ,
Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for duchenne muscular dystrophy, J. Pharmacol. Exp. Ther, vol.338, pp.784-794, 2011. ,
Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1alpha axis, Am. J. Physiol. Cell Physiol, vol.307, pp.66-82, 2014. ,
Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse, PLoS ONE, vol.7, 2012. ,
Metabogenic and nutriceutical approaches to address energy dysregulation and skeletal muscle wasting in duchenne muscular dystrophy, Nutrients, vol.7, pp.9734-9767, 2015. ,
Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening, PLoS ONE, vol.6, 2011. ,
Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of duchenne muscular dystrophy, Clin. Nutr, vol.32, pp.104-111, 2013. ,
Genetic and cellular modifiers of oxidative stress: What can we learn from fatty acid oxidation defects?, Mol. Genet. Metab, vol.110, pp.31-39, 2013. ,
Pharmacological targeting of mitochondrial complex i deficiency: The cellular level and beyond, vol.12, pp.57-65, 2012. ,
Species differences in the effects of bezafibrate as a potential treatment of mitochondrial disorders, Cell Metab, vol.14, pp.715-716, 2011. ,
Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span, Cell Metab, vol.8, pp.157-168, 2008. ,
An examination of resveratrol's mechanisms of action in human tissue: Impact of a single dose in vivo and dose responses in skeletal muscle ex vivo, PLoS ONE, vol.9, 2014. ,
Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance, Cell Metab, vol.16, pp.658-664, 2012. ,
Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans, Cell Metab, vol.14, pp.612-622, 2011. ,